Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash & Equivalents (2016 - 2025)

Coherus Oncology's Cash & Equivalents history spans 13 years, with the latest figure at $88.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 29.45% year-over-year to $88.9 million; the TTM value through Dec 2025 reached $88.9 million, down 29.45%, while the annual FY2025 figure was $88.9 million, 29.45% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $88.9 million at Coherus Oncology, down from $103.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $417.2 million in Q4 2021 and bottomed at $16.1 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $142.6 million (2024), against an average of $186.2 million.
  • The largest annual shift saw Cash & Equivalents crashed 95.04% in 2023 before it soared 1509.01% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $417.2 million in 2021, then plummeted by 84.77% to $63.5 million in 2022, then surged by 61.91% to $102.9 million in 2023, then rose by 22.45% to $126.0 million in 2024, then dropped by 29.45% to $88.9 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Cash & Equivalents are $88.9 million (Q4 2025), $103.4 million (Q3 2025), and $216.9 million (Q2 2025).